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ABSTRACT
Two major limitations to achieve efficient homing
endonuclease-stimulated gene correction using
retroviral vectors are low frequency of gene target-
ing and random integration of the targeting vectors.
To overcome these issues, we developed a reporter
system for quick and facile testing of novel
strategies to promote the selection of cells that
undergo targeted gene repair and to minimize the
persistence of random integrations and
non-homologous end-joining events. In this
system, the gene target has an I-SceI site
upstream of an EGFP reporter; and the repair
template includes a non-functional EGFP gene, the
positive selection transgene MGMTP140K tagged
with mCherry, and the inducible Caspase-9 suicide
gene. Using this dual fluorescent reporter system it
is possible to detect properly targeted integration.
Furthermore, this reporter system provides an effi-
cient approach to enrich for gene correction events
and to deplete events produced by random integra-
tion. We have also developed a second reporter
system containing MGMTP140K in the integrated
target locus, which allows for selection of primary
cells with the integrated gene target after trans-
plantation. This system is particularly useful for
testing repair strategies in primary hematopoietic
stem cells. Thus, our reporter systems should
allow for more efficient gene correction with less
unwanted off target effects.
INTRODUCTION
Traditional retrovirus-based gene therapy approaches are
based on semi-random provirus integration of therapeutic
transgenes in target cells. Clinical trials utilizing this
type of technology for the treatment of patients with
monogenic inherited disorders, namely X-linked severe
combined immunodeﬁciency (X-SCID) (1), Adenosine
deaminase deﬁciency severe combined immunodeﬁciency
(ADA-SCID) (2) and X-linked Chronic granulomatous
disease (X-CGD) (3) have produced promising results.
However, the occurrence of several adverse events as con-
sequence of insertional mutagenesis in the X-SCID trials
(4,5) in addition to the clonal expansion observed in the
CGD patients (3) have exposed the limitations of this
technology. Recently, promising alternatives have
emerged with the potential to circumvent this safety
issue by using engineered homing endonucleases (6,7) or
zinc-ﬁnger nucleases (8) to direct the processes of gene
correction and targeted gene insertion. This approach
allows for targeted insertion of a therapeutic gene
at a predetermined locus or the modiﬁcation of a disease
gene in its native locus. To date, homing endonucleases
and zinc-ﬁnger nucleases have been used in numerous
species to generate site-speciﬁc DNA double-strand
breaks that, if repaired by homologous recombination,
lead to targeted gene correction (8,9).
LAGLIDADG homing endonucleases are ideal for
genome editing because they recognize very long DNA
sequences, between 14 and 40bp, and although they
tolerate some sequence degeneracy, the frequency of
random cleavage is very low (10). Homing endonucleases
have been used successfully in numerous studies of gene
correction employing in vitro and in vivo models (11,12).
In light of these promising results, signiﬁcant efforts are
currently being made to engineer homing endonucleases
with reduced toxicity (13), and to modify their speciﬁcity
to efﬁciently cleave disease genes loci that may be cor-
rected through this approach (6,14).
Several monogenic disorders found in dogs such as
X-linked severe combined immunodeﬁciency (15),
Duchenne muscular dystrophy (16) and hemophilia (17)
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Thus, the dog represents a highly relevant pre-clinical
animal model for the study of targeted gene correction
of genetic disorders. Nevertheless, proof-of-concept
studies in the canine model are required to validate the
feasibility of this approach to gene therapy.
We have previously shown that expression of
methylguanine methyltransferase P140K (MGMTP140K),
a mutant enzyme that in contrast to wild-type MGMT is
not inhibited by O6-benzylguanine (O6BG), allows for
efﬁcient and stable selection of gene-modiﬁed hematopoi-
etic stem cells in both canine and non-human primate
models (18,19). Here we took advantage of this selection
mechanism to test strategies to improve the efﬁciency of
targeted genome editing approaches. In one of the
reporter systems we describe here, MGMTP140K expres-
sion mediates the positive selection of cells that have
undergone targeted gene correction. This approach is
useful when the gene-corrected cells do not have a selective
advantage relative to the non-corrected counterparts.
Additionally, we included a negative selection marker, an
induciblecaspase-9gene(20),tofacilitatetheeliminationof
integration events that are not generated by homologous
recombination, i.e. repair substrate captured at the site of
I-SceI cleavage or randomly integrated. This dual-selection
approach represents a novel mechanism to facilitate the
enrichment of cells that have undergone site-directed gene
correction.
In the other reporter system we developed,
MGMTP140K expression allows for the selection of the
cells with the integrated target locus prior to targeting
studies. This type of system would be useful for the
in vitro and in vivo characterization of gene repair
strategies in the context of genetic disease where all of
the cells would harbor the genomic loci for targeted inte-
gration and relatively low levels of gene correction would
lead to therapeutic beneﬁt (i.e. X-SCID).
MATERIALS AND METHODS
Vector production
To generate integrating lentivirus vectors, HEK 293T
cells were transiently transfected with the VSV-G expres-
sion plasmidpMD2.G (kindly provided by Didier
Trono—E ´ cole Polytecnique Fe ´ de ´ rale de Lausanne,
Switzerland—, and Luigi Naldini—Fondazione San
Raffaele, Milan, Italy), the packaging plasmid
pCMVR8.74 (kindly provided by Didier Trono and
Luigi Naldini) and the vector of interest following
a protocol previously described (21) with two modiﬁca-
tions. Speciﬁcally, PEI-mediated gene transfer was used
instead of Calcium phosphate, and 6mg of pMD2.G
were utilized instead of 9.5mg. Viral particles were
concentrated by overnight centrifugation at 7200g, and
the viral titer was determined by infecting human osteo-
sarcoma cells (HT1080) with serial dilutions of the viral
preparation followed by either Q-PCR or detection of the
ﬂuorescent transgene by FACS.
To produce integrase-deﬁcient lentiviruses (IDLVs),
HEK 293T cells were transiently transfected as described
before (22), with the vector, the VSV-G expression
plasmidpMD2.G and the packaging plasmid psPax2
(Addgene# 12260), which contains a point mutation in
the integrase gene (D64V). The virus preparation was
then concentrated at 8500g overnight. The viral titer was
determined by p24 ELISA using Alliance p24 Antigen
ELISA kit (Perkin-Elmer) according to the manufactur-
er’s protocol.
Quantitative PCR
The virus titer of the target vector N-stopEGFP target
was determined by quantitative PCR as described previ-
ously (18).
Gene correction on D-17 cells with the integrated
I-EGFP target
A lentiviral vector encoding the I-EGFP gene target was
used to transduce D-17 cells (obtained from ATCC) at a
low multiplicity of infection of 0.02. The cells were subject
to two rounds of FACS sort until >95% of the cells were
EGFP positive. Subsequently, 1 10
5 D-17 cells with the
integrated target were plated one day before transduction
IDLVs encoding the repair substrate, 3-19EGFP and
I-SceI driven by a SFFV promoter. The day of the trans-
duction, the culture medium was replaced and supple-
mented with 8mg/ml protamine sulfate, and 100ng/ml of
HIV-1 p24 of each IDLV were added to the cells.
For the negative selection of random integrants, the
cells were treated three times with 1mM of synthetic
dimerizer AP20187 (kindly provided by Ariad
Pharmaceuticals, Inc, Cambridge MA); treatment with
vehicle alone, i.e. 100% ethanol, was performed as
control. The cells were allowed to recover and then
treated three times with 50mM O6-benzylguanine
(O6BG) and 200mM 1,3-Bis(2-chloroethyl)-1-nitrosourea
(BCNU). The phenotypes of the cells were evaluated via
FACS. The following primers were used to amplify the
gene target: hPGKf2-50-GTG TTC CGC ATT CTG
CAA GCC TC-30 and EGFPr-50-CTT GTG GCC GTT
TAC GTC GCC G-30 and the amplicons were sequenced
as described above. To evaluate the presence of the
iCaspase9 transgene and differentiate homologous recom-
bination from NHEJ, the following primers were utilized:
mCherry[nucleotide 639]-50-CAC CAT CGT GGA ACA
GTA CG-30 and SIN-LTR[nucleotide 26]-50-TCG TTG
GGA GTG AAT TAG CC-30 with 200ng of genomic
DNA as template.
Gene correction on D-17 cells with the integrated
N-stopEGFP target
A lentiviral vector encoding the N-stopEGFP gene target
was used to transduce D-17 cells (canine osteosarcoma) at
a multiplicity of infection of 0.9. The transduced cells were
subject to three rounds of treatment with 50mM O6BG
and 200mM BCNU in order select for cells with
chromosomally integrated targets.
A total of 1 10
5 D-17 cells with the integrated target
were plated one day before transduction with IDLVs ex-
pressing the repair substrate, C-14EGFP and I-SceI
driven by a SFFV promoter. The day of the transduction,
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8mg/ml protamine sulfate. Subsequently, various amounts
of HIV-1 p24 of each IDLV were added to the cells and
EGFP+ cells were quantiﬁed by FACS 48–72h after
transduction.
EGFP+ D-17 cells generated by gene correction were
puriﬁed through FACS sorting to >90% EGFP+.
Genomic DNA was extracted (Gentra Puregene Cell
Kit, QIAGEN) and the gene target was ampliﬁed by
PCR using the Phusion
TM Flash High-Fidelity PCR
Master Mix (Finnzymes) with the following primers:
hPGK-forward 50-CAC GTC GGC AGT CGG CTC
CCT CG-30 and EGFP target-reverse 50-CTC GTC CAT
GCC GAG AGT GAT C-30. The amplicon (799bp) was
subcloned into a pCR4-TOPO vector (Invitrogen)
following the manufacturer’s instructions and then
sequenced using standard procedures.
RESULTS
Gene correction of D-17 cells with the integrated
I-EGFP target
As shown in Figure 1a, the gene target in this reporter
system is referred to as I-EGFP, and it consists of a
PGK promoter that drives the expression of an EGFP
transgene that contains a recognition site for I-SceI
11-bp upstream of the EGFP start codon. The repair
template, named 3-19EGFP, consists of a PGK
promoter that drives the expression of an mCherry-
tagged MGMTP140K transgene, and a non-ﬂuorescent
mutant EGFP transgene that lacks 48bp corresponding
to aminoacids 3–19. This repair template contains
regions of homology with the target locus in the PGK
promoter and the EGFP gene that facilitate homologous
recombination. Thus, if I-SceI-driven gene correction
occurs, the EGFP positive cells that contain the integrated
gene target become EGFP negative, mCherry positive and
with the knock-in of MGMTP140K acquire resistance to
treatment with O6BG and BCNU (Figure 1a).
Importantly, capture of the repair template at the site of
the I-SceI-mediated double-strand break (23) will acquire
the same phenotype; however, because the repair template
vector includes an inducible Caspase-9 transgene, these
events can be eliminated through treatment with the
Caspase-9 activating synthetic dimerizer AP20187. Also,
if random integration of the repair template takes place,
the cells become EGFP positive, mCherry positive, and
are also sensitive to AP20187 due to the expression of
the inducible Caspase-9 gene (Figure 1a).
To model the proposed dual-selection approach, a poly-
clonal culture of D-17 cells with stably integrated I-EGFP
gene targets was transduced with two IDLVs, one
encoding the 3-19EGFP repair template and the other
encoding I-SceI as indicated in Figure 1a. The anticipated
results of the transduction and selection processes are
shown in the schematic FACS plot shown in the top
panel of Figure 1b. The co-transduction of D-17 cells
generated the following new cell populations (Figure 1b,
middle panel): EGFP and mCherry double positive cells
derived from the random integration events of the repair
template; EGFP and mCherry double negative cells that
were predicted to correspond to targets repaired through
non-homologous end joining (NHEJ); and EGFP negative
mCherry positive cells that originated from targeted gene
correction or from the capture of the repair template at
the site of the double-strand break caused by I-SceI
cleavage. Analysis of the target locus from the puriﬁed
EGFP and mCherry double negative fraction showed
that in 8 out 11 sequences analyzed, the target locus had
undergone insertions or deletions that impaired EGFP
expression (Supplementary Figure).
To eliminate the cells that randomly integrated the
repair template or that captured it at the site of the
break induced by I-SceI, the cultures were subjected to
iterative treatments with the synthetic dimerizer
AP20187. This regimen allowed for the elimination of
such cells as indicated by the depletion of
EGFP
+mCherry
+ cells as shown in Figure 1b, bottom
panel. Importantly, the selection with AP20187 led to a
change in the ratio of gene corrected events to random
integrants from  1:1 to  3:1.
To select for the cells that had undergone gene correc-
tion (EGFP
negmCherry
+), the cultures were treated with
O6BG, a potent inhibitor of wild-type MGMT but not
MGMTP140K, and the alkylating agent BCNU. The





neg cells demonstrates that this
treatment allowed for the efﬁcient selection of cells that
express MGMTP140K (Figure 1b, bottom panel).
Signiﬁcantly, these results indicate that the combination
of the two selection mechanisms allows for the enrichment
of the cells that had undergone targeted gene correction
and the elimination of unmodiﬁed or cells with random
integration events. These selection mechanisms result in a
change in the original ratio of gene corrected events to
random integrants from  1:1 to up to  14:1.
To further evaluate the efﬁciency of the negative selec-
tion with AP20187, the presence of the iCaspase-9 trans-
gene in cultures subjected to gene correction and to the
positive and negative selection regimens was evaluated by






subsets. Next, the DNA sequence corresponding to
mCherry and the 30 LTR from the provirus was ampliﬁed
with primers as indicated by solid arrows in Figure 1a.
If the iCaspase-9 gene is present, due to the lack of hom-
ologous recombination, an amplicon of 3178bp is
produced; conversely, if the iCaspase-9 gene is absent,
because of homologous recombination, the fragment
produced has only 1429bp. The results shown in Figure
1c clearly indicate that in the EGFP
neg mCherry
+ subset,
which contains cells that have undergone gene correction
or captured the repair DNA at the I-SceI cleavage site, the
most abundant species is 1429bp in length. In contrast, in
the EGFP and mCherry double positive cell fraction,
which corresponds to random integration events of the
repair, the most abundant species is 3178bp. These
results demonstrate that the negative selection regimen
effectively depleted the cells that did not undergo gene
correction and that continued to express iCaspase-9.
PAGE 3 OF 8 Nucleic AcidsResearch, 2012, Vol.40,No. 2 e14Figure 1. Gene correction on D-17 cells with the integrated I-EGFP target. (a) Schematic representation of the gene targeting reporter system.
The non-integrating I-SceI expression vector, the integrated gene target with the I-SceI recognition site, and the non-integrating repair template are
shown along with the anticipated corrected locus. Abbreviations are: LTR, long terminal repeat; CAR, Cis-acting region; W, Woodchuck hepatitis
virus post-transcriptional regulatory element; P, Phosphoglycerate kinase promoter; G, Enhanced Green Fluorescent Protein; mCh, mCherry; S,
Spleen focus-forming virus promoter. The arrows represent the primers used for detection of the iCaspase-9 gene. (b) Results of ﬂow cytometry
analysis. Top panel: Diagram of a FACS plot indicating the phenotypes produced after lentiviral transduction and selection of D-17 cells with the
integrated target I-EGFP. Middle panel: Flow cytometry plots of cells transduced with one or two integrase-deﬁcient lentiviral vectors that deliver
the repair template or I-SceI. These are the phenotypes of the cells 45 days after transduction. Bottom panel: Treatment with the dimerizer AP20187
results in a signiﬁcant reduction in the number of EGFP
+mCherry
+ cells, which correspond to random integrants of the repair substrate. Treatment
with O6BG and BCNU to cultures already treated with AP20187 eliminates the mCherry
neg cells, which correspond to cells with an intact target
(EGFP positive) or with a target repaired through NHEJ disrupting EGFP expression. These results are representative of two different experiments.





+ subsets through FACS sorting (FACS plots shown at the right) before DNA ampliﬁcation.
The molecular weight markers (kb) are shown on the left.
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In the reporter system described above, we used FACS
sorting to enrich for the cells that contain the integrated
target; however, in order to generate a system that could
be more easily transferred into the in vivo setting, we
designed another reporter system that takes advantage
of the MGMTP140K selection method that allows for
in vitro and in vivo selection of cells with an integrated
target prior to gene repair studies. Thus, in this second
reporter system, the target locus, here referred to as
N-stopEGFP, consisted of a mutant EGFP gene that
was rendered non-functional by mutating the third and
fourth codons to stop codons, and contained the recogni-
tion site for I-SceI 11-bp upstream of the non-functional
EGFP start codon. The gene target locus also contained
the spleen focus-forming virus (SFFV) promoter driving
expression of MGMTP140K (Figure 2a). The repair sub-
strate, named C-14EGFP, consisted of another
non-functional mutant EGFP that lacked 42bp in the
30-end of the gene, corresponding to 14 amino acids
(Figure 2a). In this reporter system, gene correction
stimulated by I-SceI cleavage leads to functional EGFP
expression, which is analogous to the strategy described by
Elliot et al. for gene correction of the neomycin resistance
gene (24).
D-17 cells were transduced with a lentiviral vector
encoding the target locus and polyclonal cultures
were selected by treatment with O6BG and BCNU.
Gene marking analysis showed high levels of integrated
target with cells containing on average 0.9 proviral
copies per genome. Next, the cells with the integrated
N-stopEGFP gene target were transduced with IDLVs
that delivered I-SceI and the C-14EGFP repair
template. This co-transduction resulted in expression of
a functional EGFP as a result of gene correction as
shown in Figure 2b. To establish an optimal ratio of
I-SceI-to-repair substrate and to achieve the highest
possible level of gene correction in this cell line, the cells
were treated with different amounts of each IDLV and
analyzed for proper gene targeting indicated by EGFP
expression. The results indicated that a 1:1 ratio
(Figure 2b), and 5mg/ml p24 of each IDLV (Figure 2c),
produced the highest level of gene correction with min-
imal toxicity to the cells. Importantly, the number of
EGFP+ cells generated by gene correction was stable
over time.
To conﬁrm the repair of the gene target at the molecular
level, EGFP+D-17 cells produced by gene correction were
enriched through FACS sorting so that >90% of the cells
in the culture were EGFP positive (Figure 2d). The EGFP
gene was then ampliﬁed by PCR with a primer set that
ampliﬁes the target gene but not the repair substrate.
Speciﬁcally, the forward primer was located in the
hPGK promoter and the reverse primer was located in
the region of the EGFP sequence that the repair substrate
lacks in the 30-end. Sequence analysis of 73 clones
conﬁrmed that 30 of them (41%) correspond to the cor-
rected gene target (Figure 2e).
DISCUSSION
Here we describe the design and implementation of two
reporter systems that incorporate strategies that consider-
ably improve gene editing approaches. In the ﬁrst reporter
system, I-SceI-driven correction of an EGFP target locus
results in clones that are converted to EGFP negative,
mCherry positive, and can be selected through expression
of the MGMTP140K transgene. Unwanted random inte-
gration of the repair template results in clones that become
EGFP and mCherry (MGMTP140K) double positive, but
because they also express the inducible Caspase-9 gene,
they can be depleted using the dimerizer AP20187. With
this system, we were able to signiﬁcantly shift the original
ratio of gene corrected events to random integrants from
 1:1 to up to  14:1.
Because in this ﬁrst system MGMTP140K expression
mediates the positive selection of cells that have
undergone targeted gene correction, this system parallels
conditions in which the gene-corrected cells lack a selective
growth advantage and therefore a selectable marker is
required to improve engraftment or increase the percent-
age of gene-modiﬁed cells after transplantation to thera-
peutic levels, like is the case of b-thalassemia (25).
Moreover, the incorporation of the inducible Caspase-9
marker constitutes an additional safety measure that
helps circumventing the risk of malignancy due to
random integration events that could lead to proto-
oncogene activation. Importantly, since the
MGMTP140K and the inducible Caspase-9 transgenes
have been safely and efﬁciently used in previous in vivo
studies (18,20), this system could also be adaptable to
animal models of targeted gene correction in hematopoi-
etic stem cells. This is a signiﬁcant advantage over previ-
ously described gene targeting methods that use neomycin
resistance and Herpesvirus thymidine kinase for
positive and negative selection, respectively (26), because
such genes cannot be safely used to select cells of the
hematopoietic system due to their strong
immunogenicity (27).
In the second reporter system, I-SceI-driven gene cor-
rection of a non-functional EGFP gene leads to functional
EGFP expression. In D-17 cells with the integrated target
we were able to achieve gene correction in >8% of the
cells, and this population of cells remained stable over
several weeks.
In this system, selection with MGMTP140K allows for
the enrichment of cells with integrated targets to nearly
100% prior to gene targeting studies. This makes it a
useful model system in that it mimics a genetic disease
scenario, such as X-SCID or ADA-SCID, where the
entire hematopoietic system has a target for gene correc-
tion and as is especially the case with X-SCID even low
levels of gene correction could lead to a therapeutic
beneﬁt. A system like this will help elucidate the necessary
conditions for efﬁcient gene correction of cells of the hem-
atopoietic system using homing endonucleases.
In summary, here we describe the development of two
reporter systems to evaluate novel and sensitive strategies
to enhance gene correction driven by LAGLIDAG
homing endonucleases. One of these reporter systems
PAGE 5 OF 8 Nucleic AcidsResearch, 2012, Vol.40,No. 2 e14Figure 2. Gene correction on D-17 cells with the integrated N-stopEGFP target. (a) Schematic representation of the reporter system. The target locus,
which was integrated into the genome using a lentiviral vector, includes a mutant EGFP gene, referred to as N-stopEGFP, with a recognition site for
the I-SceI upstream of the EGFP start codon. The target also encodes the MGMTP140K transgene for positive selection. The repair substrate consists
of a carboxy-terminal truncated non-functional mutant EGFP, C-14EGFP. The corrected locus encodes a functional copy of the EGF gene.
(b) Assessment of the optimal ratio of donor DNA to I-SceI needed to achieve gene correction using IDLVs in D-17 cells. (c) Evaluation of the
optimal amount of IDLVs required for maximum levels of gene correction. (d) FACS sort-mediated selection of D-17 cells with the integrated target
that underwent EGFP gene correction. (e) Results of sequence analysis of the target locus in the FACS-sorted cells. The results indicate that 41% of the
sequences obtained from the enriched cultures were the product of gene correction induced homologous recombination between the target and repair
template (clones 2 and 5 in the subset shown here). Clone 1 demonstrated gene repair via NHEJ with 1bp insertion in the I-SceI cleavage site.
e14 Nucleic Acids Research, 2012,Vol. 40,No. 2 PAGE 6 OF 8contains the selectable markers MGMTP140K and
iCaspase-9, which together allow for considerable enrich-
ment of gene corrected cells while minimizing both
random integration and NHEJ events. In the other
system, selection through MGMTP140K allows for the
selection of cells with the integrated gene target prior to
gene correction. Thus, our approaches should facilitate
safe and efﬁcient in vivo applications of targeted gene
correction.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figure.
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